The Federal Trade Commission and seven US states have moved to hold Martin Shkreli in contempt of court, accusing him of influencing biopharma stock trading. The regulatory action represents an escalation in scrutiny of Shkreli's activities in the biotechnology sector.
The contempt charges suggest Shkreli may have violated previous orders or agreements related to his conduct in financial markets. If successful, the action could result in additional penalties or restrictions on his involvement in securities trading.